Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Diabetes Mellitus: Introduction

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Denosumab-Induced Hypocalcemia after Billroth II Gastric Bypass Surgery.

Case reports in endocrinology·2020

Same author

Durability of the effect of online diabetes training for medical residents on knowledge, confidence, and inpatient glycemia.

Journal of diabetes·2012

Same author

Effect of case-based training for medical residents on inpatient glycemia.

Diabetes care·2011

Same author

Effect of case-based training for medical residents on confidence, knowledge, and management of inpatient glycemia.

Postgraduate medicine·2011

Same author

Lactation after normal pregnancy is not associated with blood glucose fluctuations.

Diabetes care·2007

Same author

Relationship between aldosterone and progesterone in the human menstrual cycle.

The Journal of clinical endocrinology and metabolism·2006

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

New therapies for diabetes.

¹Division of Endocrinology, Mount Sinai School of Medicine, New York, New York 10029, USA. dina.green@mountsinai.org

Clinical Cornerstone

|March 25, 2008

Summary

Gut hormones are crucial for blood glucose control. Novel medications targeting these hormones, like GLP-1 agonists and DPP-IV inhibitors, may reverse type 2 diabetes by preserving beta-cell mass.

Area of Science:

Endocrinology
Metabolic Diseases
Pharmacology

Background:

The gut's role in blood glucose homeostasis is increasingly recognized.
Type 2 diabetes mellitus (DM) involves critical loss of beta-cell mass and function.
Novel therapeutic targets are emerging for type 2 DM management.

Purpose of the Study:

To explore the potential of gut hormone-targeting medications in type 2 DM.
To evaluate the impact of GLP-1 agonists and DPP-IV inhibitors on beta-cell mass.
To assess the possibility of reversing type 2 DM progression with these agents.

Main Methods:

Review of current research on gut hormones and diabetes pathophysiology.
Analysis of mechanisms of action for GLP-1 agonists and DPP-IV inhibitors.

Related Experiment Videos

Last Updated: Jul 6, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Evaluation of preclinical and clinical data regarding beta-cell effects.

Main Results:

GLP-1 agonists and DPP-IV inhibitors target key aspects of type 2 DM.
Both drug classes show potential for expanding beta-cell mass.
These agents may counteract the decline in beta-cell function seen in type 2 DM.

Conclusions:

GLP-1 agonists and DPP-IV inhibitors show promise in type 2 DM treatment.
Potential to reverse type 2 DM natural history by preserving beta-cell mass.
Further long-term studies are required to confirm efficacy and role in diabetes management.